Innate Pharma (IPHA) EBITDA (2019 - 2025)

Innate Pharma (IPHA) has reported EBITDA for 7 consecutive years, with -$59.5 million the latest figure, recorded in Q4 2025.

• Quarterly EBITDA rose 2.15% year-over-year to -$59.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$179.2 million (down 75.84% YoY) and the FY2025 annual result came in at -$61.5 million, down 4.72% from the prior year.
• EBITDA slipped to -$59.5 million in Q4 2025 per IPHA's latest filing, from -$28.9 million in the prior quarter.
• Over the last five years, EBITDA for IPHA reached as high as -$452905.8 in Q2 2023 and fell as low as -$60.8 million in Q4 2024.
• A 5-year average of -$32.5 million and a median of -$28.9 million in 2021 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA soared 65.64% — and 2024, when it slumped 6511.31%.
• Year by year, EBITDA stood at -$54.4 million in 2021, then soared by 65.64% to -$18.7 million in 2022, then soared by 42.76% to -$10.7 million in 2023, then sank by 468.27% to -$60.8 million in 2024, then grew by 2.15% to -$59.5 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$59.5 million, -$28.9 million, and -$60.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.